AstraZeneca PLC Cedear AZN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 1.55B
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 4.18
- Price/Sales
- 1.17
- Dividend Yield (Trailing)
- 1.79%
- Dividend Yield (Forward)
- 1.79%
- Dividend Payment Schedule
- Mar, Sep
- Total Yield
- 1.79%
Company Profile
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 96,100
- Website
- https://www.astrazeneca.com
Competitors
Valuation
|
Metric
|
AZN
|
NVS
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 4.18 | 13.57 | 44.80 |
Price/Book Value | 1.34 | 6.45 | 8.47 |
Price/Sales | 1.17 | 4.80 | 5.36 |
Price/Cash Flow | 4.62 | 14.16 | 16.10 |
Price/Earnings
AZN
NVS
MRK
Financial Strength
|
Metric
|
AZN
|
NVS
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.66 | 0.55 | 0.71 |
Current Ratio | 0.89 | 0.86 | 1.32 |
Interest Coverage | 7.99 | 11.90 | 4.28 |
Quick Ratio
AZN
NVS
MRK
Profitability
|
Metric
|
AZN
|
NVS
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 9.00% | 14.74% | 6.27% |
Return on Equity (Normalized) | 21.69% | 39.06% | 16.68% |
Return on Invested Capital (Normalized) | 14.36% | 21.25% | 9.82% |
Return on Assets
AZN
NVS
MRK
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|sk&PdDL | LOCK|JL | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|hZ!<Bky | LOCK|cqT | $617B | |||
| AbbVie Inc
ABBV
| LOCK|wvtg$Z | LOCK|m% | $464B | |||
| Merck & Co Inc
MRK
| LOCK|&@j$l?b | LOCK|G! | $356B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|?&m<#@m | LOCK|zCz | $333B | |||
| Novartis AG ADR
NVS
| LOCK|@%<V&sC | LOCK|^^ | $266B | |||
| AstraZeneca PLC
AZN
| LOCK|#!hyr@R | LOCK|?% | $248B | |||
| Amgen Inc
AMGN
| LOCK|RP<pm>K | LOCK|<> | $218B | |||
| Gilead Sciences Inc
GILD
| LOCK|q!%>z< | LOCK|c! | $179B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|%%>%>pv | LOCK|q@ | $165B |
United States